Jamie S. Lin, M.D., F.A.S.N.
Department of Emergency Medicine, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2010 | University of Nebraska Medical Center College of Medicine, Omaha, Nebraska, US, Medicine, M.D |
| 2005 | University of Pennsylvania, Philadelphia, Pennsylvania, US, Biological Basis of Behavior, B.A |
Postgraduate Training
| 2017-2019 | Clinical Fellow, Onco-Nephrology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2015-2017 | Research Fellow, Nephrology, University of Pennsylvania, Philadelphia, Pennsylvania |
| 2013-2015 | Clinical Fellow, Nephrology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania |
| 2011-2013 | Resident, Internal Medicine, Baylor College of Medicine, Houston, Texas |
| 2010-2011 | Intern, Internal Medicine, Baylor College of Medicine, Houston, Texas |
Board Certifications
| 2015 | American Board of Internal Medicine, Nephrology |
| 2013 | American Board of Internal Medicine |
Experience & Service
Academic Appointments
Instructor, Department of Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2020
Administrative Appointments/Responsibilities
Co-Director Immuno-Oncology Toxicity (IOTOX) Nephritis, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present
Institutional Committee Activities
Member, Division of Internal Medicine Research Committee, 2021 - Present
Member, Division of Internal Medicine Research Education Subcommittee, 2021 - 2024
Member, The University of Texas MD Anderson IOTOX Working Group, 2019 - Present
Honors & Awards
| 2022 | Immune checkpoint inhibitor associated nephritis: Identifying predictors of immunotoxicity, NIH/NCI Loan Repayment Program Award |
| 2021 | Best Oral Presentation, Basic Research Forum for Emerging Kidney Scientists, American Society of Nephrology and American Physiological society |
| 2020 | Fellow of ASN, American Society of Nephrology |
| 2019 | Dose Adjustment for Renal Replacement Therapy (DARRT) Project 2019, Commission on Cancer, The University of Texas MD Anderson Cancer Center |
| 2017 | Sharon Anderson Research Fellow, American Society of Nephrology |
| 2016 | First place, National Young Investigator’s Forum, National Kidney Foundation |
| 2016 | Karen L. Campbell American Society of Nephrology Travel Award, American Society of Nephrology |
| 2016 | Third place, Mid-Atlantic Regional Young Investigator Forum, Johns Hopkins University School of Medicine |
| 2014 | Origins of Renal Physiology Mount Desert Island Biologic Laboratory Scholarship, Mount Desert Island Biologic Laboratory |
| 2011 | Kidney STARS Travel Award, American Society of Nephrology |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Meath, CM, Simon, B, Mehta, RS, Kebriaei, P, Lin JS, Lin J. Terlipressin for Sinusoidal Obstruction Syndrome-Associated Acute Kidney Injury: A Novel Application. Clin Kidney J, 2025.
- Long JP, Singh S, Dong Y, Yee C, Lin JS. Urine proteomics defines an immune checkpoint-associated nephritis signature. J Immunother Cancer, 2025. e-Pub 2025. PMID: 39863302.
- Shivaraj K, Tchakarov A, Dong Y, Lin JS. Tofacitinib for the treatment of refractory immune checkpoint inhibitor-associated immune nephritis. Clin Kidney J 17(5), 2024. e-Pub 2024. PMID: 38803394.
- Singampalli KL, Harris CN, Yee C, Lin JS, Lillehoj PB. Highly Reusable Electrochemical Immunosensor for Ultrasensitive Protein Detection. Advanced Sensor Research, 2024. e-Pub 2024. PMID: 39640072.
- Fayle SE, Palaskas NL, Siddiqui BA, McQuade JL, Lin JS, Subudhi SK, Patel AB, Jenq RR, Shah AY, Spelman AR, Sun M, Marble BH, Wang Y. Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events. J Natl Compr Canc Netw 22(5), 2024. e-Pub 2024. PMID: 38190801.
- Bohat R, Liang X, Chen Y, Xu C, Zheng N, Guerrero A, Hou J, Jaffery R, Egan NA, Li Y, Tang Y, Unsal E, Robles A, Chen S, Major AM, Elldakli H, Chung SH, Liang H, Hicks MJ, Du Y, Lin JS, Chen X, Mohan C, Peng W. Fas(lpr) gene dosage tunes the extent of lymphoproliferation and T cell differentiation in lupus. Clin Immunol 258:109874, 2024. e-Pub 2024. PMID: 38113962.
- Turcotte AE, Glass WF, Lin JS, Burger JA. Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib. Leuk Res Rep, 2023. e-Pub 2023. PMID: 37457553.
- Singh S, Long JP, Tchakarov A, Dong Y, Yee C, Lin JS. Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis. JCI Insight, 2022. e-Pub 2022. PMID: 36472921.
- Singh S, Clemente LC, Parra ER, Tchakarov A, Yang C, Li Y, Long JP, Yee C, Lin JS. Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates. OncoImmunoloy 11(1), 2022. e-Pub 2022. PMID: 36185804.
- Gupta S, Strohbehn IA, Wang, Q, et al IC. Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer. Kidney Int 102(4):930-935, 2022. e-Pub 2022. PMID: 35964800.
- Ratanasrimetha P, Reddy VD, Kala J, Tchakarov A, Glass WF, Msaouel P, Lin JS. Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma. Front Immunol 13:898811, 2022. e-Pub 2022. PMID: 35967405.
- Abdelrahim M, Mamlouk O, Lin H, Lin JS, Page V, Abdel-Wwahab N, Swan J, Selamet U, Yee C, Diab A, Suki W, Abudayyeh A. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis. Oncoimmunology, 2022. e-Pub 2022. PMID: 34104543.
- Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ, Ostermann M, Herrmann SM, Abudayyeh A, Anand S, Glezerman I, Motwani SS, Murakami N, Wanchoo R, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, Seigneux S, Campedel L, Kitchlu A, Shin DS, Rangarajan S, Deshpande P, Coppock G, Eijgelsheim M, Seethapathy H, Lee MD, Strohbehn IA, Owen DH, Husain M, Garcia-Carro C, Bermejo S, Lumlertgul N, Seylanova N, Flanders L, Isik B, Mamlouk O, Lin JS, Garcia P, Kaghazchi A, Khanin Y, Kansal SK, Wauters E, Chandra S, Schmidt-Ott KM, Hsu RK, Tio MC, Sarvode Mothi S, Singh H, Schrag D, Jhaveri KD, Reynolds KL, Cortazar FB, Leaf DE, Investigators IC. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer 9(10), 2021. e-Pub 2021. PMID: 34625513.
- Lin JS, Mamlouk O, Selamet U, Tchakarov A, Glass WF, Sheth RA, Layman RM, Dadu R, Abdelwahab N, Abdelrahim M, Diab A, Yee C, Abudayyeh A. Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology 10(1), 2021. e-Pub 2021. PMID: 33643693.
- Lin JS, Wang DY, Mamlouk O, Glass WF, Abdelrahim M, Yee C, Abudayyeh A. Immune Checkpoint Inhibitor Associated Reactivation of Primary Membranous Nephropathy Responsive to Rituximab. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33020246.
- Mamlouk O, Lin JS, Abdelrahim M, Tchakarov A, Glass WF, Selamet U, Buni M, Abdelwahab N, Abudayyeh A. Checkpoint inhibitor–related renal vasculitis and use of rituximab. Journal of Immunotherapy Cancer 8(2), 2020. e-Pub 2020. PMID: 32718987.
- Galvan DL, Long J, Green N, Chang BH, Lin JS, Schumacker P, Truong LD, Overbeek P, Danesh FR. Drp1S600 phosphorylation regulates mitochondrial fission and progression of nephropathy in diabetic mice. J Clin Invest 130(7):2807-2823, 2019. e-Pub 2019. PMID: 31063459.
- Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, Lin JS, Abdel-Wahab N, Tayar J, Lu H, Suarez-Almazor M, Tannir N, Yee C, Diab A, Abudayyeh A. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer 7(1):2, 2019. e-Pub 2019. PMID: 30612580.
- Mamlouk O, Lin JS, Zhang H, Glass WF, Amaria RN, Lahoti A, Workeneh BT. Tubulointerstitial and intraglomerular metastasis with subsequent development of tumor lysis syndrome in a patient with advanced metastatic melanoma. Journal of Onco-Nephrology, 2018. e-Pub 2018.
- Ingersoll MA, Chou YW, Lin JS, Yuan TC, Miller DR, Xie Y, Tu Y, Oberley-Deegan RE, Batra SK, Lin MF. p66Shc regulates migration of castration-resistant prostate cancer cells. Cell Signal 46:1-14, 2018. e-Pub 2018. PMID: 29462661.
- Lin FC, Lin JS, Kim S, Walker JR. A rare diaphragmatic ureteral herniation case report: endoscopic and open reconstructive management. BMC Urol 17(1):26, 2017. e-Pub 2017. PMID: 28381270.
- Lin JS, Jeon JS, Fan Q, Wong HN, Palmer MB, Holzman LB. ARF6 mediates nephrin tyrosine phosphorylation-induced podocyte cellular dynamics. PLoS One 12(9):e0184575, 2017. e-Pub 2017. PMID: 28880939.
- Lin JS, Susztak K. Podocytes: the Weakest Link in Diabetic Kidney Disease?. Curr Diab Rep 16(5):45, 2016. e-Pub 2016. PMID: 27053072.
- Lin JS, Shi Y, Peng H, Shen X, Thomas S, Wang Y, Truong LD, Dryer SE, Hu Z, Xu J. Loss of PTEN promotes podocyte cytoskeletal rearrangement, aggravating diabetic nephropathy. J Pathol 236(1):30-40, 2015. e-Pub 2015. PMID: 25641678.
- Liu J, Johnson TV, Lin JS, Ramirez SH, Bronich TK, Caplan S, Persidsky Y, Gendelman HE, Kipnis J. T cell independent mechanism for copolymer-1-induced neuroprotection. Eur J Immunol 37(11):3143-54, 2007. e-Pub 2007. PMID: 17948266.
- Veeramani S, Igawa T, Yuan TC, Lin FF, Lee MS, Lin JS, Johansson SL, Lin MF. Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells. Oncogene 24(48):7203-12, 2005. e-Pub 2005. PMID: 16170380.
- Morris RJ, Liu Y, Marles L, Yang Z, Trempus C, Li S, Lin JS, Sawicki JA, Cotsarelis G. Capturing and profiling adult hair follicle stem cells. Nat Biotechnol 22(4):411-7, 2004. e-Pub 2004. PMID: 15024388.
- Lee MS, Igawa T, Chen SJ, Van Bemmel D, Lin JS, Lin FF, Johansson SL, Christman JK, Lin MF. p66Shc protein is upregulated by steroid hormones in hormone-sensitive cancer cells and in primary prostate carcinomas. Int J Cancer 108(5):672-8, 2004. e-Pub 2004. PMID: 14696093.
Editorials
- Khan R, Lin JS, Mata DA. Depression and Suicide among Physician Trainees. JAMA 72(8), 2015.
- Mata DA, Lin JS, Ramos MA. Can we predict future depression in residents before the start of clinical training?. Medical Education 49(7):741-742, 2015.
Abstracts
- Abudayyeh A, Suo L, Lin H, Mamlouk O, Yee C, Lin JS, Tchakarov A. A Pathological Immunological Approach in Evaluating ICI Induced Nephritis. American Society of Nephrology, 2022. e-Pub 2022.
- Abudayyeh A, Suo L, Lin H, Mamlouk O, Yee C, Tcharkarov A, Lin JS. Predictors of ICI renal toxicity: a pathological approach. Society of Immunotherapy for Cancer, 2021. e-Pub 2021.
- Reddy V, Kala J, Msaouel P, Glass WF, Mamlouk O, Abudayyeh A, Lin JS. Treatment of PLA2R-Negative Membranous Nephropathy in the Setting of Immune Checkpoint Inhibitor and Renal Cell Carcinoma. American Society of Nephrology Annual Meeting, 2021. e-Pub 2021.
- Lin JS, Tchakarov A, n A, Houssein S, Bentebibel S, Abdelrahim M, Yee C, Diab A, Abudayyeh A. Tertiary lymphoid structure gene signature detected in immune checkpoint inhibitor-associated renal immune related adverse event. Society of Immunotherapy for Cancer, 2021. e-Pub 2021.
- Lin JS, Wang DY, Mamlouk O, Glass WF, Abudayyeh A. Immune Checkpoint Inhibitor Associated Reactivation of Primary Membranous Nephropathy Responsive to Rituximab. American Society of Nephrology Annual Meeting, 2020. e-Pub 2020.
- Lin JS, Mamlouk O, Glass WF, Abudayyeh A. Immune Checkpoint Inhibitor Induced Kidney and Cardiac Sarcoidosis. American Society of Nephrology Annual Meeting, 2020. e-Pub 2020.
- Montanez M, Lin JS, Mamlouk O, Glass WF, Abudayyeh A. Immune Checkpoint Inhibitor Induced p-ANCA Multiorgan Vasculitis. American Society of Nephrology Annual Meeting, 2020. e-Pub 2020.
- Mamlouk O, Lin JS, Abdelrahim M, Tchakarov A, Glass WF, Selamet U, Buni M, Abudayyeh A. Checkpoint inhibitor–related renal vasculitis and use of rituximab. American Society of Nephrology Annual Meeting, 2020. e-Pub 2020.
- Lin JS, Lovisa S, Zeisberg M, Sugiimoto H, Xiao F, Calin G, Lebleu V, Kalluri R. Dicer promotes renal recovery and limits interstitial fibrosis following kidney injury. American Society of Nephrology Annual Meeting, 2019. e-Pub 2019.
- Abudayyeh A, Lin YH, Lin JS, Mamlouk O, Selamet U, Abdelrahim M. Incidence of AKI in Melanoma patients treated with immune checkpoint inhibitors. American Society of Nephrology Annual Meeting, 2019. e-Pub 2019.
- Lin JS, Long J, Chang BB, Galvan DL, Green N, Danesh FR. Deletion or inhibition of ARF6 improves albuminuria in Type 2 diabetic mice. American Society of Nephrology Annual Meeting, 2019. e-Pub 2019.
- Lin JS, Sugimoto H, Gangadhar T, Danesh FR, Lebleu V, Kalluri R. Deletion of proximal tubular cell VEGF production promotes renal fibrosis: implications for VEGF-based cancer therapy. American Society of Nephrology Annual Meeting, 2019. e-Pub 2019.
- Lin JS, Green N, Long J, Chang B, Galvan D, Danesh FR. ARF6: a possible molecular target for Diabetic Kidney Disease?. American Society of Nephrology Annual Meeting, 2018. e-Pub 2018.
- Lin JS, Mamlouk O, Glass WF, Amaria A, Lahoti A, Workeneh BT. Acute renal failure secondary to multifocal tubulointerstitial and intraglomerular metastatic malignant melanoma. International Conference OncoNephrology, 2017. e-Pub 2017.
- Lin JS, Lahoti A. Trifluridine and tipiracil-induced leukocytoclastic vasculitis with late-onset Henoch-Schönlein purpura nephritis. International Conference OncoNephrology, 2017. e-Pub 2017.
- Lin JS, Fan QF, Wong H, Jeon JS, Holzman LB. ARF6 activation is necessary for nephrin-dependent changes in podocyte cytoskeletal dynamics. American Society of Nephrology Annual Meeting, 2016. e-Pub 2016.
- Lin JS, Jeon JS, Fan QF, Holzman LB. ARF6: a new player in injury-induced podocyte effacement. American Society of Nephrology Annual Meeting, 2015. e-Pub 2015.
- Long JP, Singh S, Dong Y, Yee C, Lin JS. Novel Urine Biomarkers Associated with Immune Checkpoint Inhibitor Nephrotoxicity. American Society of Nephrology.
Book Chapters
- Mamlouk O, Lin JS, Abudayyeh A. Nephrology (Kidney). In: Managing Immunotherapy Related Organ Toxicities. Springer. Springer, 2022.
Selected Presentations & Talks
Local Presentations
- 2025. Decoding Immune Checkpoint Inhibitor-Associated Nephritis Through Urine Proteomics. Invited. Nephrology Grand Rounds. Miami, Florida, US.
- 2025. Non-invasive Diagnosis of ICI-AIN: A Urinary Proteomics Approach. Invited. Division of Internal Medicine Research Grand Rounds. Houston, Texas, US.
- 2025. Identifying Immune Checkpoint Inhibitor-Associated Nephritis through Urine Proteomics. Invited. Katz Center Research Meeting. Miami, Florida, US.
- 2023. Immune checkpoint inhibitor-associated nephritis: epidemiology, management, and surveillance. Invited. Nephrology Renal Rounds. Chicago, IL, US.
- 2023. Identifying predictors of immune checkpoint inhibitor-associated nephritis. Invited. Nephrology Research Rounds. New Haven, CT, US.
- 2022. TNF-alpha blockade for treatment of ICI-associated acute interstitial nephritis. Invited. Onco-Nephrology Conference. NYC, NY, US.
- 2021. Development of an immune signature in ICI-mediated acute interstitial nephritis. Conference. The University of Texas MD Anderson Cancer Center IOTOX Retreat. Houston, TX, US.
- 2020. Investigating Nephrotoxicity from Checkpoint Inhibitors. Invited. Baylor/Methodist Renal Grand Rounds. Houston, Texas, US.
- 2017. ARF6 and nephrin-mediated podocyte cellular events. Invited. Renal Rounds. Houston, Texas, US.
- 2016. Amyloid and its extrafibrillary components. Invited. Renal Grand Rounds. Baltimore, MD, US.
Regional Presentations
- 2022. Urinary T cells in Immune Checkpoint Inhibitor Associated Acute Interstitial Nephritis. Conference. Gulf Coast Consortium Future of Immunology. Houston, TX, US.
- 2016. ARF6 function in nephrin signaling and podocyte effacement. Conference. Philadelphia, PA, US.
- 2016. The function of ARF6 in nephrin signaling and podocyte effacement. Conference. Johns Hopkins University Mid-Atlantic Regional Young Investigator Forum, Nephrology, Basic Science Research. Boston, MA, US.
National Presentations
- 2024. Novel Urine Biomarkers Associated with Immune Checkpoint Inhibitor Nephrotoxicity. Conference. American Society of Nephrology. San Diego, CA, US.
- 2023. Utility of Urinary T cells in ICI toxicity. Invited. American Society of Onco-Nephrology. Houston, TX, US.
- 2022. Same T Cell: Different Kidney Problem. Invited. National Kidney Foundation. Boston, MA, US.
- 2021. Identification of Tertiary Lymphoid Structures in Immune Checkpoint Inhibitor Kidney Related Adverse Events. Conference. American Society of Nephrology, US.
- 2020. Fireside Chat: Mentor-Mentee Relationship, Basic Research Forum. Invited. American Physiological Society and American Society of Nephrology, US.
- 2018. ARF6: a possible molecular target for Diabetic Kidney Disease?. Conference. American Society of Nephrology. San Diego, CA, US.
- 2016. ARF6 activation is necessary for nephrin-dependent changes in podocyte cytoskeletal dynamics. Conference. American Society of Nephrology. Chicago, IL, US.
- 2016. ARF6: Shedding light on nephrin signaling and podocyte effacement. Conference. National Young Investigator’s Forum, Nephrology, Basic Science Research, National Kidney Foundation. Boston, MA, US.
- 2012. PTEN Deletion in Podocytes: A Potential General Mechanism Causing Foot Processes Effacement and Proteinuria. Conference. American Society of Nephrology. Philadelphia, PA, US.
International Presentations
- 2024. Investigating Immune Checkpoint Inhibitor-Acute Interstitial Nephritis: Insights from Urine. Invited. Institute of Biochemistry and Molecular Biology Research Conference. Taipei, TW.
- 2024. Investigating Immune Checkpoint Inhibitor-Acute Interstitial Nephritis: Insights from Urine. Invited. International Symposium for the 70th Anniversary Celebration of Kaohshiung Medical University. Kaohsiung, TW.
- 2019. Treatment side effects of immunotherapy. Invited. Oncological Forum. Tromso, NO.
Formal Peers
- 2022. IOTOX Difficult Case Review Series: Nephritis. Houston, Texas, US.
- 2021. ICI Nephrotoxicity: a guided approach to diagnosis and treatment. Houston, Texas, US.
- 2021. IOTOX Educational Series. Houston, Texas, US.
Grant & Contract Support
| Date: | 2024 - 2025 |
| Title: | Rapid Urine Test for Detecting Cancer Immunotherapy Toxicity (Bridge Funding) |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2024 - 2025 |
| Title: | Investigating Immune Checkpoint Inhibitor-Acute Interstitial Nephritis: Insights from Urine (Adverse Incident Bridge Funding) |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2024 - 2029 |
| Title: | Establishing a non-invasive immune checkpoint inhibitor nephritis signature |
| Funding Source: | NIH |
| Role: | PI |
| Date: | 2024 - 2027 |
| Title: | Rapid urine test for detecting cancer immunotherapy toxicity |
| Funding Source: | CPRIT |
| Role: | PI |
| Date: | 2021 - 2022 |
| Title: | immune Checkpoint Urine Prognostic Profiling (i.C.U.P.P.) |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2020 - 2021 |
| Title: | Research Bridge Funding |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2020 - 2021 |
| Title: | Checkpoint Inhibitor Associated‐Nephritis: Identifying Predictors of Immunotoxicity |
| Funding Source: | The University of Texas MD Anderson Cancer Center, Division of Internal Medicine Immuno-Oncology Toxicity Award Program |
| Role: | PI |
| Date: | 2019 - 2024 |
| Title: | The role of ARF6 in the progression of diabetic kidney disease |
| Funding Source: | NIH/NIDDK |
| Role: | PI |
| ID: | K08DK119466 |
| Date: | 2017 - 2019 |
| Title: | The functional role of ARF6-GEFs in nephrin-mediated podocyte cytoskeletal remodeling and endocytic nephrin trafficking |
| Funding Source: | ASN Ben J. Lipps Research Fellowship Program |
| Role: | PI |
| Date: | 2016 - 2017 |
| Title: | The role of ARF6 in cytoskeletal dynamics in podocyte injury |
| Funding Source: | NIH/NIDDK |
| Role: | PI |
| ID: | F32DK108566 |
Patient Reviews
CV information above last modified June 25, 2025